Literature DB >> 24547607

Suicide prevention as a prerequisite for recovery from severe mental illness.

Tom J Foster1.   

Abstract

For a significant number of people suffering from severe mental illness (SMI) prevention of suicide is a prerequisite for their recovery. This review summarises and interprets risk/protective factors for suicide in the context of schizophrenia and bipolar disorder, thereby enabling evidence-based suicide risk assessment and management. A history of self-harm greatly increases suicide risk among people with schizophrenia or bipolar disorder. Suicide prevention for patients with SMI necessitates constant vigilance by (mental) health and social care professionals in contact with them, particularly those with a history of self-harm, males, young people, those near illness onset, people with a family history of suicidal behaviour (especially suicide), victims of childhood abuse, those challenged by recent adverse life events (notably interpersonal conflict), people with aggressive/impulsive personality features, and those who have expressed hopelessness. Research suggests that suicide risk associated with SMI should be reduced by early intervention, restricting access to lethal means, improvement of treatment adherence, treating more patients with clozapine and lithium, assertive outreach, treating psychiatric comorbidity (depression, alcohol/drug misuse, etc.), 24-hour crisis care, timely (compulsory) hospitalization (sufficient bed provision imperative), improving psychiatric inpatient ward safety, lowering the risk of absconding from wards, appropriate use of electroconvulsive therapy, intensive follow-up postdischarge, and improving access to psychological/psychosocial interventions, notably cognitive behavioural therapy. The clinical interview is the optimum method of suicide risk assessment and locally developed risk assessment tools should not be used. Evidence-based suicide risk assessment/management within primary care and secondary mental health services warrants recurrent, mandatory training.

Entities:  

Mesh:

Year:  2013        PMID: 24547607     DOI: 10.2190/PM.46.1.b

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  5 in total

Review 1.  A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder.

Authors:  Ayal Schaffer; Erkki T Isometsä; Jean-Michel Azorin; Frederick Cassidy; Tina Goldstein; Zoltán Rihmer; Mark Sinyor; Leonardo Tondo; Doris H Moreno; Gustavo Turecki; Catherine Reis; Lars Vedel Kessing; Kyooseob Ha; Abraham Weizman; Annette Beautrais; Yuan-Hwa Chou; Nancy Diazgranados; Anthony J Levitt; Carlos A Zarate; Lakshmi Yatham
Journal:  Aust N Z J Psychiatry       Date:  2015-07-14       Impact factor: 5.744

2.  Modeling Relationships Involving Perceived Recovery Orientation of Mental Health Teams Among Quebec Mental Health Professionals.

Authors:  Marie-Josée Fleury; Judith Sabetti; Jean-Marie Bamvita
Journal:  J Behav Health Serv Res       Date:  2019-07       Impact factor: 1.505

3.  Are quantity and content of psychiatric interventions associated with suicide? A case-control study of a Swedish sample.

Authors:  Fredrik Holländare; Maria Tillfors; Axel Nordenskjöld; Tabita Sellin
Journal:  BMC Psychiatry       Date:  2020-01-09       Impact factor: 3.630

4.  Time-series analysis of trends in the incidence rates of successful and attempted suicides in Thailand in 2013-2019 and their predictors.

Authors:  Suwanna Arunpongpaisal; Sawitri Assanagkornchai; Virasakdi Chongsuvivatwong; Nattakorn Jampathong
Journal:  BMC Psychiatry       Date:  2022-08-31       Impact factor: 4.144

5.  Work-related variables associated with perceptions of recovery-oriented care among Quebec mental health professionals.

Authors:  Marie-Josée Fleury; Judith Sabetti; Guy Grenier; Jean-Marie Bamvita; Catherine Vallée; Zhirong Cao
Journal:  BJPsych Open       Date:  2018-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.